HUMA

Humacyte Inc

Add to Watchlist

Advanced Chart

2.430

+0.06(2.532%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

2.455

Open

2.370

VWAP

Vol

2.96M

Mkt Cap

376.94M

Low

2.320

Amount

EV/EBITDA(TTM)

Total Shares

119.08M

322.32M

EV/OCF(TTM)

P/S(TTM)

Humacyte, Inc. is a commercial-stage biotechnology platform company. The Company is engaged in developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a range of diseases, injuries, and chronic conditions. It is using its proprietary, scientific technology platform to engineer and manufacture acellular tissue engineered vessels (ATEVs). The Company is also in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is also engaged in the preclinical development of coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple cell and tissue applications.

3 Analyst Rating

215.64% Upside

Wall Street analysts forecast HUMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for HUMA is 7.67 USD with a low forecast of 4.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

0 Hold

0 Sell

Strong Buy

215.64% Upside

Current: 2.430

Low

4.00

Averages

7.67

High

14.00

215.64% Upside

Current: 2.430

Low

4.00

Averages

7.67

High

14.00

Benchmark

analyst

Buy

downgrade

$17 -> $14

2025-05-14

Reason

Benchmark

analyst

Price Target

$17 -> $14

2025-05-14

downgrade

Buy

Reason

Benchmark lowered the firm's price target on Humacyte to $14 from $17 and keeps a Buy rating on the shares. Humacyte launched Symvess in February and generated its first commercial product revenue during Q1, notes the analyst, who believes the company is poised to gain significant share for surgical procedures requiring vascular grafts and notes that the new product pipeline continues to move forward.

H.C. Wainwright

Buy

initiated

2025-05-14

Reason

H.C. Wainwright

Price Target

2025-05-14

initiated

Buy

Reason

H.C. Wainwright assumed coverage of Humacyte with a Buy rating and $4 price target. Humacyte's lead product, Symvess, was approved as a vascular conduit in extremity vascular trauma at the end of 2024 and management initiated U.S. commercialization of the product in February, notes the analyst, who is "encouraged" that the product achieved approximately $0.5M in the first two months of launch. The company has completed enrollment in the Phase 3 V007 study evaluating the acellular tissue engineered vessel for arteriovenous access for hemodialysis and in order to "monetize Symvess to the fullest extent," the company is conducting two additional Phase 2 studies, V002 and V004, evaluating the ATEV in peripheral artery disease, the analyst added.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$25

2025-03-31

Reason

D. Boral Capital

Jason Kolbert

Price Target

$25

2025-03-31

Maintains

Strong Buy

Reason

D. Boral Capital says the selloff in shares of Humacyte following the company's $50M capital raise is a buying opportunity. While the stock weakness reflects dilution concerns, the additional capital significantly strengthens Humacyte's financial position, the analyst tells investors in a research note. With its FDA-approved cellular tissue-engineered vessels "poised to revolutionize vascular trauma," D. Boral views the current pullback as an opportunity to accumulate shares. It keeps a Buy rating on Humacyte with a $25 price target.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$25

2025-03-28

Reason

D. Boral Capital

Jason Kolbert

Price Target

$25

2025-03-28

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

$25

2025-03-26

Reason

D. Boral Capital

Jason Kolbert

Price Target

$25

2025-03-26

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Vernon Bernardino

Strong Buy

Reiterates

$15

2025-03-12

Reason

HC Wainwright & Co.

Vernon Bernardino

Price Target

$15

2025-03-12

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Humacyte Inc (HUMA.O) is -4.15, compared to its 5-year average forward P/E of -6.04. For a more detailed relative valuation and DCF analysis to assess Humacyte Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.04

Current PE

-4.15

Overvalued PE

-1.68

Undervalued PE

-10.40

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-3.52

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.51

Undervalued EV/EBITDA

-8.56

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

804.61

Current PS

30.56

Overvalued PS

2179.47

Undervalued PS

-570.26

Financials

Annual

Quarterly

FY2025Q1

517.00K

Total Revenue

FY2025Q1

YoY :

-12.77%

-23.18M

Operating Profit

FY2025Q1

YoY :

-222.71%

39.14M

Net Income after Tax

FY2025Q1

YoY :

-203.45%

0.30

EPS - Diluted

FY2025Q1

YoY :

+3.93%

-28.83M

Free Cash Flow

FY2025Q1

71.57

Gross Profit Margin - %

FY2025Q1

7.57K

Net Margin - %

Trading Trends

Insider

Insiders areBuying! The selling amount has increased 815.68% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

13.2M

USD

0-12

Months

16.5M

USD

Bought

0-3

0.0

USD

Months

3-6

146.1K

USD

Months

6-9

16.0K

USD

Months

0-12

16.0K

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

0.0

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

3.3M

Volume

Months

6-9

0.0

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders areBuying! The selling amount has increased 815.68% over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

13.2M

USD

0-12

Months

16.5M

USD

Bought

0-3

0.0

USD

Months

3-6

146.1K

USD

Months

6-9

16.0K

USD

Months

0-12

16.0K

USD

Months

HUMA News & Events

Events Timeline

2025-07-23 (ET)

2025-07-23

08:08:39

Humacyte announces first sale of Symvess to U.S. Military Treatment Facility

2025-07-08 (ET)

2025-07-08

08:09:48

Humacyte's Symvess awarded Electronic Catalog listing approval by DoD

2025-06-09 (ET)

2025-06-09

08:12:59

Humacyte announces presentation of results from Phase 3 AV access study of V007

News

2.0

07-25NASDAQ.COM

Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts

2.0

07-24NASDAQ.COM

Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know

9.5

07-23Benzinga

GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday